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been demonstrated in patients with chronic myelogenous 
leukemia (CML). Allogeneic stem cell transplantation (ASCT) can 
be curative for patients (pts) with CML. It is not known if the 
abnormal BM angiogenesis changes following SCT. We studied 
the effect of SCT on BM microvesseI density (MVD) in CML and 
examined the prognostic value of pre and post ransplant (Tx) 
MVD. Patients and Methods: We evaluated MVD from BM 
samples obtained just prior to and at 3-5 months after ASCT in 
38 CML pts.31 pts each had either pre-Tx or post-Tx biopsies 
and 24 pts had both pre and post Tx biopsies available for com- 
parison. Microvessels were stained using immunohistochemical 
staining for vonWillebrand factor, using a labeled streptavidin- 
biotin peroxidase method. MVD was estimated by determining 
the average number of vessels in 3 hot spots examined at 400x 
magnification. The angiogenesis was graded as low (MVD < 10), 
intermediate (MVD < 20) or high (MVD >= 20). Results: The 
median MVD pre Tx for 31 pts was 14 (4-37); with 13 pts having 
high-grade angiogenesis, 12 intermediate-grade and 6 low-grade. 
The median post Tx MVD in 31 pts was 20 (range 5-36) with 16 
pts having high-grade angiogenesis, 13 intermediate-grade and 2 
low-grade. The median time between biopsies was 4 months 
(range 1-6 months). There was no significant change in the fol- 
lowing Tx (P =0.8, paired t-test). The MVD increased in 12 pts 
(median increase 8), decreased in 10 (median decrease 9) and 
remained unchanged in 2. The pre or post Tx MVD did not pre- 
dict relapse free or overall survival following SCT. The microves- 
sels in the post Tx BM demonstrated striking dilatation compared 
to the pre-Tx marrow. Conclusion: BM angiogenesis seen in 
CML does not change significantly following allogeneic SCT. 
These results are consistent with what we have observed in 
patients with nmltiple myeloma receiving high dose or conven- 
tional therapy and also with other reports. It is possible that per- 
sistent vessels may serve as a nidus for tumor relapse, however we 
were not able to demonstrate such an effect in our small group. 
This data provide further evidence against using regression of 
angiogenesis a a marker of therapeutic response, even in the con- 
text of anti-angiogenic therapy. 
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INFECTIONS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION 
(ALLO-BMT) IN SOUTH BRAZIL: LOW INCIDENCE OF INVASIVE FUN- 
GAL INFECTIONS DESPITE LOW-DOSE FLUCONAZOLE PROPHYLAXIS 
Bitte~Tcourt, H.; Segato, A.; Paz, A.; Sa~tos, 3/1.; Fischer, G.; Catelli, 
D.; BittelTcou~'t, R.; Fogliatto, L.; Fe~amtes, F.; Daudt, L.; Astigarra- 
ga, C.; F*'iedeHsch, J.; O,mere T.; Silla, L. Hospital de Cli*zicas de 
Po*'to Alegre, Porto Alegre, B*:azil. 
infections remains amain cause of morbidity and mortality after 
allo-BMT. Herein we describe our data concerning infections 
incidence until D+100 after BMT. We retrospectively reviewed 
98 patients transplanted from i2/94 to 04/02 with an HLA-identi- 
cal (n-96), 1-HLA allele mismatch (n=l) or singeneic (n=l) sibling 
donor. Graft source was bone marrow in 88 patients. Median fol- 
low-up was 3 years. Median age was 31 years. Seventy-six patients 
had malignancies (CML 45, ALL/AML 27, MDS 4). Eight-eight 
patients were CMV positive. GV}tD prophylaxis was cyclosporine 
+ methotrexate in 94 patients. Uni- and multivariate analysis were 
performed with Kaplan-Meier/log rank and Cox models respec- 
tively. Transplant-related mortality (TRM) and overall survival 
(OS) were 24% (100 days) and 54% (5 years). Acute grade 2-4 
GVt-ID incidence was 32%. Fifty-four patients presented at least 
one episode of a severe bacterial infection (septicemia, septic 
shock, and pneumonia), with a cumulative incidence of 56% until 
D+100. Most frequent bacteria isolated were Staphylococcus sp. 
(n=53), E. coli (n=7) and Klebsiella sp. (n=6). In univariate analy- 
sis, no variable influencing incidence of bacterial infections, how- 
ever, there was a tendency of less bacterial infections with a higher 
nucleated cell dose graft (p=0.11). Thirty-five patients presented 
at least one episode of CMV reactivation with a cmnulative inci- 
dence of 36%. Six patients presented a CMV disease. In multivari- 
ate analysis, presence of acute GVHD grade 2-4 (HR=2.8; CI95: 
1.43-5.46; P=0.003) and recipient age more than 18 years 
(HR=0.09; CI95: 0.01-0.64; P=0.02) were associated with a higher 
incidence of CMV infection/disease. Only three patients present- 
ed a proven or probable invasive fungal infection: 1 candidemia, 1 
Aspergillus p. infection and 1 Fusarium sp. infection until D+100. 
The incidence of bacterial and CMV infections were comparable 
to the literature. On the other hand, despite use of a relatively 
lower dose of fluconazole, incidence of fungal infection was signif- 
icanty lower than expected. In our experience, use of low-dose flu- 
conazole (200mg/d) is sufficient o provide adequate prophylaxis 
for fungal infections, decreasing BMT costs. Low incidence of 
mold infections might be explained by factors other than flucona- 
zole use. 
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DNA BASED HIGH RESOLUTION TYPING : OPTIMIZED PRESELECTION 
FOR CONFIRMATORY TYPING (CT) 
~'Vittrock, J.; Rehm, P.; Rutt, C.; Baier, D.3/I. DKMS Deutsche 
K~ochel~l~mvkspet~derdatei, T~leb J~gel~, Bade*~ l,Vi#'tte~71berg, Ge*w~a~zy. 
Search speed and monetary resources can be minimized by 
inserting a DNA based high resolution typing before r questing 
an unrelated stem ceil donor for confirmatory t ping. Therefore 
the DICMS offers the possibility to request high resolution typing 
class I and II since 1992 (at least on four digits leveI). These typ- 
ings are performed with new drawn blood samples and not with 
"stored samples", because we think that donors hould be aware of 
the importance to become apotential stem cell donor soon. With 
the introduction of optimized software and changing the workfiow 
in 2000, the turnaround time from donor contact o the transmis- 
sion of the typing results could be halved from over 20 to about 
10-13 days. The results of the high resolution typings give a very 
precise preselection of donors for an allogenic stem ceil transplan- 
tation. So the donor selected for confirmatory typing after a 
request for high resolution typing is more propable to be the suit- 
able donor. We observe asteadily increasing number of high reso- 
lution typing requests that over-strides the increasing number of 
the confirmatory t pings. High resolution typings and the return- 
ing of the confirmatory typing results by the search centers 
heighten the quality of our donor data base, reduce the workload 
for the search centers and accelerate donor searches in the future. 
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CASE REPORT OF A PATIENT WITH ADULT T-CELL LEUKEMIA/LYM- 
PHOMA (ATLL) 18 MONTHS AFTER ALLOGENEIC MATCHED RELATED 
DONOR PERIPHERAL STEM CELL TRANSPLANT 
Stola1-, K.; Uaugha1~, H,~.; Salzma~, D.; Lopez, R.; Gavcia, ,4. Boise 
Marrow Tr.allsphmt, Universi O, of Alabama at Bi~wJi*Nha'm, Bi~w~ing- 
ham, AL. 
The long term prognosis for persons affected with Adult t-cell 
leukemia/lymphoma associated with HTLV -1 disease is dismal. 
We report a case in which a patient is without evidence of disease 
at 18 months after peripheral blood stem ceil transplant. Her 
brother was her matched onor. She was treated with Fludarabine 
and Busulfex conditioning regimen prior to transplant. She is thiry 
nine years old, African American, diagnosed in November 2000. 
She presented with palpable adenopathy, hepatomegaly, elevated 
WBC of forty-four thousand and eight nine percent lymphocytes, 
hypercalcemia, elevated LDH, pleural effilsion, pericardial effu- 
sion and multiple areas of adenopathy in her chest. HTLV 1 anti- 
body was reactive. Bone marrow biopsy and thoracentesis were 
both consistent with ATLL. Complex chromosome abnormalities 
were present including trisomy 3 and 7. She received 2 cycles of 
adriamycin, VP-16, dexamethasone with decrease in adenopathy 
and was brought o transplant after passing the requisite pretrans- 
plant organ testing. She received 16 doses of high dose Busulfex 
per pharmacokinetic dosing every six hours, Fludarabine at 
40mg/m2, one dose daily for 5 consecutive days, and antithymo- 
cyte globulin 15mg/kg for four doses. Her graft versus host dis- 
ease prevention included long course methotrexate and 
cyclosporine. Evaluations at 100 days, 200 days, 1 year and 18 
months show no radiographic evidence of disease. FISH studies 
consistently show 100% male donor chromosomes. Bone marrow 
aspirate and biopsy at one year shows normal tissue morphology 
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with no evidence of disease. Flow cytometry shows no aberrant 
populations. Cytogenetic testing is pending at this report. HTLV 
1 viral load studies show consistent decrease in viral load. The 




HOST-REACTIVE MEMORY T LYMPHOCYTES ALONE DO NOT INDUCE 
MORE SEVERE GRAFT-VERSUS-HOST DISEASE 
Chert, B.J.; Cui, X.; C,~ao, N.J. Dltke U, ivevsity Medical Center, 
Din'ham, NC. 
Memo W T lylnphocytes are thought o mediate more rapid and 
profound memory irnmunc response. In this study, we tested 
whether it is true in graft-versus-host disease (GVHD). C57BL/6 
mice (H2 b) were injected with irradiated BALB/c (H2 d) spleen 
cells intraperitoneally at least 8 weeks before they were used as 
immunized onors. Splenic T cells (>90% pure) were harvested 
from these immunized animals and separated into CD62L + (>90% 
pure) and CD62L- (>99% pure) populations by magnetic beads. 
CD62L + T cells include both naive and memory T cells, while 
CD62L- T cells contain memory T cells but no naive T cells. We 
next compared the alloreactivity and the ability to induce GVHD 
(C57BL/6 to BALB/c) of CD62L T cells with those of unseparat- 
ed and CD62L + T cells. Despite CD62L (memory) T cells con- 
tain similar numbers of interferon-y-secreting cells upon response 
to host antigens as detected by enzyme-linked immunospot assay, 
CD62L- T cells had dramatically decreased ability to induce 
GVHD in BALB/e mice compared to unseparated and CD62L + T 
cell controls (Table). However, CD62L T cell recipients did 
develop GVHD as documented by weight loss (Table) and histo- 
logic changes. Similar results were observed when the mice immu 
nized with BCL1 cells (a BALB/c-or igin B cell 
lymphoma/leukelnia cell line) were used as donors. We conclude 
that host-reactive m mm T T cells alone have decreased ability to 
induce GVHD compared with a mixture of naive and memory T
cells. Memory T cells obtained from tumor cel l - immunized 
donors may be a unique source of T cells for tumor imnmnothera- 
py because they do not induce severe GVHD. 
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A CRITICAL ROLE FOR CD4+CD25 ÷ SUPPRESSOR CELLS IN CON- 
TROLLING GVHD AFTER DLI IN MURINE BONE MARROW CHIMERAS 
Xia, G., Yah, X.; Cao, 0.; T77titt, R.L.; Johnson, B.D. Depmv:me,t of 
Pediatrics, ~Iedit:al College of IUisconsi{z, 3/lilwzzkee, ~Z 
A murine model of allogeneic bone marrow (BM) transplanta- 
tion (C57BL/6[B6]-into-AKR/J) was used to further define the 
role of CD4+CD25 * T cells in controling GVHD after DLI and 
their potential  therapeutic application. B6- into-AKR BM 
chimeras were depleted of CD25 + cells in vivo with anti-CD25 
mAb or transplanted with BM from CD25 K° donors so that the 
BM recipients would be devoid of donor-derived CD25 + cells. 
Depletion of CD25 + cells in vivo (>70% depletion) significantly 
increased the severity of DLI- induced GVHD as indicated by 
body weight loss and increased mortality as compared to nonde- 
pleted control mice. GVHD was even more intense in mice trans- 
planted with CD25 k° BM. Enhanced GVHD after CD25 deple- 
tion was seen after DLI of either 30 million or 60 million donor 
splenocytes. To test the ability of CD25 ~ cells to persist and 
expand in vivo, nylon-wool enriched, immunomagnetically select- 
ed fresh CD25 ÷ cells were adoptively transferred into syngeneic 
nude mice. These cells progressively expanded (CD4 and CD8 
subsets) over 5 months in syngeneic nude mice. Approximately 
30% of the cells at 2-wk and less than 10% at 20-wk were still 
CD25 *. Various conditions for activation and expansion of CD25+ 
suppressor cells were examined. Freshly-isolated B6 CD25 ÷ cells 
were cultured with rIL-2 in the presence of (1) immoblized anti- 
CD3 mAb plus soluble anti-CD28 mAb, (2) magnetic beads coat- 
ed with anti-CD3 and anti-CD28 mAbs, and (3) CD32/4-1BB lig- 
and double-transfected K562 tmnor cells (K562DT) "loaded" 
with anti CD3 and anti-CD28 mAbs. The K562DT cells induced 
superior short-term expansion of CD4+CD25+cells (>10 fold after 
7-10 days of culture). Imnmblized anti-CD3 plus soluble anti- 
CD28 preferentially expanded the CD8 subset from <3% in fresh 
CD25+cells to >75% of the total cells after 1 week of culture. Ex 
vivo expanded CD25 ÷ cells were more suppressive than fresh cells 
added to primary mixed lymphocyte cultures in which 50% of 
stimulation inhibition was achieved at a 1:8 CD25*/CD25 ratio 
for ex vivo expanded CD25 + as compared to a 1:1 ratio required 
for fresh cells. Studies looking at the ability of ex vivo expanded 
CD25 + ceils to persist/expand in vivo, and the GVHD-protective 
role of freshly-isolated versus ex vivo expanded CD25" cells coad- 
ministered with DLI, are in progress. 
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TCR TRANSGENIC HEMATOPOETIC STEM CELLS ENGRAFT INTO 
NON-TRANSGENIC RECIPIENTS AND EVOLVE ANTIGEN-SPECIFIC 
T-CELLS 
Krnft, D.L.; Ranheim, E.A.; Weissman, I.L. Pediatric 
Hematology/Oncology and Dept of Pathology, Sta~zfo'rd University 
School of ~/ledicine, Staj~'ord, CA. 
We hypothesized that genetically modified hematopoetic stem 
cells (HSC) transduced with a specific tmnor antigen specific 
TCR may, when given as a fraction of a donor hematopoetic 
sten, cell graft, lead to engraftment of tumor antigen specific T-  
cells and facilitate directed Graft vs Malignancy (GVL). ~¢\7e are 
developing a model system for exploring the feasibility of this 
approach. An important component of evaluating such a strategy 
is determining the ability for donor TCR-transgenic HSC to 
engraft into non-transgenic recipients, and to determine the 
ldneties of antigen specific T-cell  engraftment. P14 mice are 
transgenic for the elass-I restricted TCR specific to LCMV-Gly- 
coprotein-33. Bone marrow was obtained from P14 CD45.2 
TCR-Transgenic mice and transplanted into lethally irradiated 
non-transgenic, ongenic CD45.1 recipients. Of the 500, 000 
marrow cells in the graft, 0%, 10%, 25%, 50% or 100% was 
from a P14 donor, the remainder from CD45.1 congenic mar- 
row. The number of LCMV-GP33 specific T-cells in the periph- 
eral blood was measured weekly with MHC-H-2  D(b)GP33 
tetramer. Control P14 mice contained an average of 25% CD8+ 
cells in the peripheral blood, of which 82% were GP33 tetramer 
positive. We found that TCR-transgenic  P14 bone marrow 
would engraft, and result in measurable donor derived LCMV- 
GP specific CD8+ T-cells. The fraction of tetramer positive T- 
ceils in peripheral blood increased in correlation to the percent- 
age of P 14 bone marrow transplanted. Four weeks post-transplant 
CD45.2, tetramer+ T-cells made up a mean 3.5% of peripheral 
bloo.d in mice which had received 100% P14 donor marrow, 
1.3% from 50% P14 donor, and .63% from a 25% P14 marrow 
donor. By week five, tetramer + cells had increased to 9.4% of 
blood cells in mice receiving 100% P14 donor marrow, 4.7% 
from 50% P14 marrow and .74% from 25% donor. Engraftment 
of tetramer+ T-cel ls increased in weeks 5 and 6 and then 
remained stable. 7 weeks post transplant in mice receiving 50% 
P14 marrow, 8.8% of peripheral cells were CD8+, of which 
43.7% were tetramer+. 25% P14 transgenic donor recipients 
evolved 5.5% CD8+ T-cells of which 7.8% were tetramer posi- 
tive. These results suggest hat bone marrow containing TCR- 
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